Aa
Aa
A
A
A
Close
Avatar universal

Arbutus Provides Corporate Update and Announces Second Quarter 2016

https://globenewswire.com/news-release/2016/08/04/861960/0/en/Arbutus-Provides-Corporate-Update-and-Announces-Second-Quarter-2016-Financial-Results.html

Recent Highlights and Developments

Ongoing Phase II study of ARB-1467 evaluating two doses of ARB-1467 (0.2 mg/kg and 0.4 mg/kg) in HBV infected patients.

Preclinical combination data presented at the 5th Antiviral Drugs Research and Development Conference showing additive anti-HBV activity when combining AB-423 (core protein/capsid assembly inhibitor) with entecavir or interferon.

LNP-enabled messenger RNA (mRNA) delivery data presented at the 32nd Annual Meeting of the Japan Society of Drug Delivery System show potent delivery of mRNA with very high and persistent expression levels.

Data presented on new Lipid Nanoparticle (LNP) compositions for messenger RNA (mRNA) delivery at the 2016 Controlled Release Society Annual Meeting and Exposition demonstrating the improved potency and tolerability associated with our new LNP formulations for delivery of mRNA payloads.

Topline results reported from the completed Phase I/II TKM-PLK1 clinical study in patients with advanced hepatocellular carcinoma (HCC) including: 51% of subjects showed overall stable disease (SD) according to RECIST criteria, 22% of subjects showed an overall partial response (PR) according to Choi response criteria, and tumor density reduction of up to 59% was observed. Arbutus intends to explore partnership opportunities to enable further study of TKM-PLK1 in HCC.

After extensive preclinical evaluation of TLR9 agonist ARB-1598, Arbutus has concluded that the data do not support further development of ARB-1598. As a result, Arbutus is discontinuing development of ARB-1598.

As disclosed in a webcast investor conference presentation in June, Arbutus will not be filing an IND (or equivalent) in 2016 for a cccDNA formation inhibitor due to additional exploration of the biology of this program. Arbutus remains highly committed to developing new product candidates to impact cccDNA.
Upcoming Milestones

2H16: Preclinical data release on multiple pipeline programs, including results from preclinical combination studies of proprietary pipeline candidates
3Q16: Single dose HBsAg reduction data from the ARB-1467 (RNAi) Phase II trial in HBV-infected patients
4Q16: HBsAg reduction data from the multiple dose portion of the Phase II trial testing ARB-1467 in HBV-infected patients
2H16: File IND (or equivalent) for core protein/capsid assembly inhibitor
2H16: File IND (or equivalent) for ARB-1740 (RNAi)
2017: Initiate clinical combination studies with two or more proprietary product candidates
0 Responses
Sort by: Helpful Oldest Newest
Have an Answer?

You are reading content posted in the Hepatitis B Community

Didn't find the answer you were looking for?
Ask a question
Popular Resources
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.